BRAF and neoplasm: In the remaining tumor types, 57% of the samples harbored a (likely) pathogenic mutation and/or amplification, including amplifications of ERBB2 and EGFR, and mutations in BRAF and POLE. In general, TP53 was the most frequently mutated gene: 1 or 2 TP53 mutations were observed in 46% (334/728) of the tumor samples [43].